StreetAlpha
13F holdings · Q3 2026

venBio Partners

San Francisco, CA · files as venBio Partners LLC
Know the moment venBio Partners filesYou follow venBio Partners An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1776382

venBio Partners reported 9 stocks worth $496M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PBLS (34.3%), PHVS (28.5%) and ATTO (14.4%). Compared with Q2 2026, the fund opened new positions in ATTO, YARW and LSTA, trimmed PHVS and ALMS and sold out of HRMY.

Latest filing: what venBio Partners did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
3 new0 added2 trimmed1 sold outBought about $84.4M · sold about $25.5M
New 3
Added 0

None

Trimmed 2
Sold out 1

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$496M−4.5% vs last quarter
Stocks held93 new · 1 sold out
Top 5 weight93.2%very concentrated
Turnover22%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
PBLS
Parabilis Medicines Inc Com
$170M34.3%5.3MNo change2 of 8
2
PHVS
Pharvaris N V
$141M28.5%4.5M−184K (−4%)8 of 8
3
ATTO
Attovia Therapeutics Inc
$71.7M14.4%4.2MNew position1 of 8
4
ACHV
Achieve Life Sciences Inc
$47.9M9.7%5.9MNo change2 of 8
5
ALMS
Alumis Inc
$31M6.3%4.2M−337K (−7%)8 of 8
6
ALXO
Alx Oncology Hldgs Inc
$17.9M3.6%12.9MNo change8 of 8
7
YARW
Yarrow Bioscience Inc
$12.5M2.5%555KNew position1 of 8
8
LYEL
Lyell Immunopharma Inc
$3.3M0.7%338KNo change6 of 8
9
LSTA
Lisata Therapeutics Inc
$225K0.1%156KNew position1 of 8

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
HRMY
Harmony Biosciences Hldg
$17.2M472K

Reported value

last 8 quarters
$171MQ4 '24
$124MQ1 '25
$115MQ2 '25
$176MQ3 '25
$216MQ4 '25
$281MQ1 '26
$519MQ2 '26
$496MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

venBio Partners 13F FAQ

What does venBio Partners own?

venBio Partners reported 9 stocks worth $496M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PBLS (34.3%), PHVS (28.5%) and ATTO (14.4%). The table above lists every position in the filing (the top 10 without an account).

What did venBio Partners buy and sell in Q3 2026?

Compared with Q2 2026: 3 new positions, 0 added to, 2 trimmed and 1 sold out. New positions include ATTO, YARW and LSTA. It sold all of HRMY.

When will venBio Partners file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is venBio Partners's portfolio worth?

The Q3 2026 filing reports $496M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.